VanEck Vectors Generic Drugs ETF
GNRX
GNRX was delisted on the 4th of April, 2019.
4 hedge funds and large institutions have $287K invested in VanEck Vectors Generic Drugs ETF in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
33% more funds holding
Funds holding: 3 → 4 (+1)
37% less capital invested
Capital invested by funds: $458K → $287K (-$171K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$239K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$22.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$354K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$75.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $239K | +$239K | +10,809 | New |
|
|
FDCDDQ
2
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $25.3K | – | – | – |
|
|
3
Bank of America
Charlotte,
North Carolina
| $22K | +$22.1K | +1,000 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $1K | -$75.2K | -3,395 | -99% |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$354K | -15,717 | Closed |
|
GNRX Hedge Fund Activity: Q3 2017 in Review
4 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in VanEck Vectors Generic Drugs ETF (GNRX) for Q3 2017, worth a combined $287K — down 37% from $458K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new GNRX positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $239K. The largest seller was Citadel Advisors, exiting entirely with an estimated $354K sold.
- 4 institutional investors held VanEck Vectors Generic Drugs ETF (GNRX) as of Q3 2017, up from 3 in Q2 2017.
- Funds reported $287K of VanEck Vectors Generic Drugs ETF stock for Q3 2017, down 37% quarter-over-quarter.
- 2 funds opened new VanEck Vectors Generic Drugs ETF positions in Q3 2017 and 1 closed out, a net change of +1 holder.
- The largest VanEck Vectors Generic Drugs ETF buyer in Q3 2017 was Jane Street, an estimated $239K added.
- The largest VanEck Vectors Generic Drugs ETF seller in Q3 2017 was Citadel Advisors, an estimated $354K sold.
Based on aggregated 13F filings for Q3 2017.